FEMLYV

Growth

norethindrone acetate/ethinyl estradiol

Millicent Pharma

NDAORALTABLET, ORALLY DISINTEGRATING

Approved

Jul 2024

Lifecycle

Growth

Competitive Pressure

0/100

Mechanism of Action

ovulation.

Indications (1)

pregnancy () Limitations of Use The efficacy in females of reproductive potential with a body mass index of more than 35 kg/m has not been evaluated (

Loss of Exclusivity

LOE Date

Jun 24, 2041

186 months away

Patent Expiry

Jun 24, 2041

Exclusivity Expiry

Jul 22, 2027

Patent Records (1)

Patent #	Expiry	Type	Use Code
12178824	Jun 24, 2041	Product	—

Company

Millicent Pharma

Ireland - Dundalk

External Resources

Full prescribing information

FDA approval history

Drug nomenclature & identifiers